Search

Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Washington School of Medicine, University of Michigan, and the Institute of Cancer Research Royal Marsden Hospital.

… Wednesday, July 6, 2016 Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber

MSK’s SPORE grant in leukemia has the potential to develop practice-changing approaches, evaluation, and management that may lead to improved patient outcomes for AML.

… Tuesday, September 7, 2021 The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone

Learn why post-doctoral researcher Mijin Kim believes Memorial Sloan Kettering is an excellent choice for early career biomedical researchers, as she enjoys her recognition as a STAT Wunderkind, class of 2023.

… Tuesday, October 17, 2023 Mijin Kim, PhD, a postdoctoral researcher at Memorial Sloan Kettering Cancer Center (MSK), has been recognized with the prestigious  Wunderkind award by STAT , the well-regarded news site covering science and medicine. Each year, STAT seeks to find “the best researchers in health

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough findings for new treatment approaches in several cancer indications at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9 to 13 in Paris. Highlights included clinically meaningful benefits for new treatment strategies in advanced bladder cancer, endometrial cancer, and renal cell carcinoma. Additionally, MSK experts shared their perspectives on previously reported groundbreaking trials of new treatment approaches in colorectal cancer and HER2-low metastatic breast cancer.

… Tuesday, October 11, 2022 Advanced Bladder Cancer: Promising Results for Enfortumab Vedotin Plus Pembrolizumab MSK has been spearheading the development and testing of antibody-drug conjugates — novel biopharmaceuticals that deliver precise payloads of anti-cancer agents directly to cancer cells — alone

During a virtual awards ceremony, MSK and the Robbins Family Foundation recognized eight distinguished MSK staff members and one team for their exemplary service. Each member was honored with the 2021 Robbins Family Award for Nursing Excellence.

… Wednesday, May 12, 2021 Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK

Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the National Cancer Institute (NCI).

… Tuesday, October 11, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the  National Cancer Institute (NCI) . The long-term goal of the grant is to demonstrate that prospective

Memorial Sloan Kettering’s 37th annual academic Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement shared the spotlight on May 19.

… Tuesday, July 5, 2016 An afternoon ceremony on May 19 celebrated MSK’s 37th annual Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement. Presided over by MSK President and CEO Craig Thompson , it recognized students who conducted their doctoral dissertation

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

… Monday, October 31, 2016 Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment

Learn how our donor community is supporting MSK research and education.

… Thursday, April 1, 2021 Every day, your dollars are accelerating today’s most daring discoveries straight into lifesaving care. Read more to learn about your impact. The Society of Memorial Sloan Kettering Winter Lunch On February 3, The Society of MSK hosted its eighth annual Winter Lunch to support

A prominent research grant will enable MSK doctors and scientists to advance the treatment of bladder cancer.

… Friday, May 31, 2019 Summary The National Cancer Institute recently awarded MSK a prestigious SPORE grant for bladder cancer research. Learn about how MSK researchers will use the $6.5 million award to gain insights into how the disease develops and responds to treatment. Bladder cancer is the fifth